vs
Side-by-side financial comparison of Dover Corporation (DOV) and Henry Schein (HSIC). Click either name above to swap in a different company.
Henry Schein is the larger business by last-quarter revenue ($3.4B vs $2.1B, roughly 1.6× Dover Corporation). Dover Corporation runs the higher net margin — 13.4% vs 2.9%, a 10.5% gap on every dollar of revenue. On growth, Dover Corporation posted the faster year-over-year revenue change (12.5% vs 7.7%). Over the past eight quarters, Henry Schein's revenue compounded faster (4.1% CAGR vs -1.8%).
Dover Corporation is an American conglomerate manufacturer of industrial products. The Downers Grove, Illinois-based company was founded in 1955. As of 2021, Dover's business was divided into five segments: Engineered Products, Clean Energy and Fueling, Imaging & Identification, Pumps & Process Solutions and Climate and Sustainability Technologies. Dover is a constituent of the S&P 500 index and trades on the New York Stock Exchange under the symbol DOV. Dover was ranked 448 in the 2024 Fortu...
Henry Schein, Inc. is an American distributor of health care products and services, with operations in 33 countries and territories. It is the world’s largest provider of health care solutions to office-based dental and medical practitioners. For 14 consecutive years, the company has been named as one of the World's Most Ethical Companies by Ethisphere, most recently in 2025.
DOV vs HSIC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $3.4B |
| Net Profit | $282.1M | $101.0M |
| Gross Margin | 39.1% | 30.9% |
| Operating Margin | 16.5% | 4.7% |
| Net Margin | 13.4% | 2.9% |
| Revenue YoY | 12.5% | 7.7% |
| Net Profit YoY | 22.2% | 7.4% |
| EPS (diluted) | $2.06 | $0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $3.4B | ||
| Q3 25 | $2.1B | $3.3B | ||
| Q2 25 | $2.0B | $3.2B | ||
| Q1 25 | $1.9B | $3.2B | ||
| Q4 24 | $1.5B | $3.2B | ||
| Q3 24 | $2.0B | $3.2B | ||
| Q2 24 | $2.2B | $3.1B |
| Q1 26 | $282.1M | — | ||
| Q4 25 | $282.1M | $101.0M | ||
| Q3 25 | $302.0M | $101.0M | ||
| Q2 25 | $279.1M | $86.0M | ||
| Q1 25 | $230.8M | $110.0M | ||
| Q4 24 | $1.4B | $94.0M | ||
| Q3 24 | $347.1M | $99.0M | ||
| Q2 24 | $281.8M | $104.0M |
| Q1 26 | 39.1% | — | ||
| Q4 25 | 39.1% | 30.9% | ||
| Q3 25 | 40.1% | 30.7% | ||
| Q2 25 | 39.9% | 31.4% | ||
| Q1 25 | 40.0% | 31.6% | ||
| Q4 24 | 41.4% | 31.1% | ||
| Q3 24 | 38.5% | 31.3% | ||
| Q2 24 | 37.7% | 32.5% |
| Q1 26 | 16.5% | — | ||
| Q4 25 | 16.5% | 4.7% | ||
| Q3 25 | 18.2% | 4.9% | ||
| Q2 25 | 17.3% | 4.7% | ||
| Q1 25 | 15.9% | 5.5% | ||
| Q4 24 | 14.0% | 4.9% | ||
| Q3 24 | 16.8% | 4.9% | ||
| Q2 24 | 17.0% | 5.1% |
| Q1 26 | 13.4% | — | ||
| Q4 25 | 13.4% | 2.9% | ||
| Q3 25 | 14.5% | 3.0% | ||
| Q2 25 | 13.6% | 2.7% | ||
| Q1 25 | 12.4% | 3.5% | ||
| Q4 24 | 96.4% | 2.9% | ||
| Q3 24 | 17.5% | 3.1% | ||
| Q2 24 | 12.9% | 3.3% |
| Q1 26 | $2.06 | — | ||
| Q4 25 | $2.06 | $0.85 | ||
| Q3 25 | $2.19 | $0.84 | ||
| Q2 25 | $2.02 | $0.70 | ||
| Q1 25 | $1.67 | $0.88 | ||
| Q4 24 | $10.38 | $0.75 | ||
| Q3 24 | $2.51 | $0.78 | ||
| Q2 24 | $2.04 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $156.0M |
| Total DebtLower is stronger | $3.3B | $2.3B |
| Stockholders' EquityBook value | $7.4B | $3.2B |
| Total Assets | $13.4B | $11.2B |
| Debt / EquityLower = less leverage | 0.45× | 0.71× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $156.0M | ||
| Q3 25 | — | $136.0M | ||
| Q2 25 | — | $145.0M | ||
| Q1 25 | — | $127.0M | ||
| Q4 24 | — | $122.0M | ||
| Q3 24 | — | $126.0M | ||
| Q2 24 | — | $138.0M |
| Q1 26 | $3.3B | — | ||
| Q4 25 | $3.3B | $2.3B | ||
| Q3 25 | $3.1B | $2.2B | ||
| Q2 25 | $3.1B | $2.1B | ||
| Q1 25 | $3.0B | $2.0B | ||
| Q4 24 | $2.9B | $1.8B | ||
| Q3 24 | $3.0B | $1.9B | ||
| Q2 24 | $3.0B | $1.9B |
| Q1 26 | $7.4B | — | ||
| Q4 25 | $7.4B | $3.2B | ||
| Q3 25 | $7.7B | $3.4B | ||
| Q2 25 | $7.4B | $3.4B | ||
| Q1 25 | $7.1B | $3.3B | ||
| Q4 24 | $7.0B | $3.4B | ||
| Q3 24 | $5.7B | $3.5B | ||
| Q2 24 | $5.4B | $3.5B |
| Q1 26 | $13.4B | — | ||
| Q4 25 | $13.4B | $11.2B | ||
| Q3 25 | $13.4B | $11.1B | ||
| Q2 25 | $13.2B | $10.9B | ||
| Q1 25 | $12.6B | $10.5B | ||
| Q4 24 | $12.5B | $10.2B | ||
| Q3 24 | $11.9B | $10.6B | ||
| Q2 24 | $11.3B | $10.3B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | 0.45× | 0.71× | ||
| Q3 25 | 0.40× | 0.64× | ||
| Q2 25 | 0.41× | 0.61× | ||
| Q1 25 | 0.42× | 0.59× | ||
| Q4 24 | 0.42× | 0.54× | ||
| Q3 24 | 0.53× | 0.54× | ||
| Q2 24 | 0.55× | 0.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $381.0M |
| Free Cash FlowOCF − Capex | — | $338.0M |
| FCF MarginFCF / Revenue | — | 9.8% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | — | 3.77× |
| TTM Free Cash FlowTrailing 4 quarters | — | $573.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $543.9M | $381.0M | ||
| Q3 25 | $424.2M | $174.0M | ||
| Q2 25 | $212.3M | $120.0M | ||
| Q1 25 | $157.5M | $37.0M | ||
| Q4 24 | $439.0M | $204.0M | ||
| Q3 24 | $353.2M | $151.0M | ||
| Q2 24 | $203.7M | $296.0M |
| Q1 26 | — | — | ||
| Q4 25 | $487.0M | $338.0M | ||
| Q3 25 | $370.1M | $141.0M | ||
| Q2 25 | $151.4M | $88.0M | ||
| Q1 25 | $109.3M | $6.0M | ||
| Q4 24 | $385.0M | $168.0M | ||
| Q3 24 | $325.0M | $117.0M | ||
| Q2 24 | $162.8M | $259.0M |
| Q1 26 | — | — | ||
| Q4 25 | 23.2% | 9.8% | ||
| Q3 25 | 17.8% | 4.2% | ||
| Q2 25 | 7.4% | 2.7% | ||
| Q1 25 | 5.9% | 0.2% | ||
| Q4 24 | 25.8% | 5.3% | ||
| Q3 24 | 16.4% | 3.7% | ||
| Q2 24 | 7.5% | 8.3% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 1.3% | ||
| Q3 25 | 2.6% | 1.0% | ||
| Q2 25 | 3.0% | 1.0% | ||
| Q1 25 | 2.6% | 1.0% | ||
| Q4 24 | 3.6% | 1.1% | ||
| Q3 24 | 1.4% | 1.1% | ||
| Q2 24 | 1.9% | 1.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.93× | 3.77× | ||
| Q3 25 | 1.40× | 1.72× | ||
| Q2 25 | 0.76× | 1.40× | ||
| Q1 25 | 0.68× | 0.34× | ||
| Q4 24 | 0.31× | 2.17× | ||
| Q3 24 | 1.02× | 1.53× | ||
| Q2 24 | 0.72× | 2.85× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOV
Segment breakdown not available.
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
